NRx-101, a potential new antibiotic, shows minimal impact on gut and vaginal flora in a rodent model.
NRx Pharmaceuticals reports new data on NRX-101, a clinical-stage drug, that shows no measurable damage to intestinal or vaginal flora in a rodent model, unlike antibiotics such as ciprofloxacin. NRX-101, with minimal impact on gut and vaginal flora, could be the first antibiotic for complicated urinary tract infections (cUTI) and pyelonephritis without the risk of causing C. diff infection or vaginal yeast infection, potentially saving lives from antibiotic-induced C. diff infections.
April 17, 2024
4 Articles